COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,225 Articles (22,733 medRxiv, 8,492 bioRxiv)

Most recent first Previous |  Page 811: Articles 8101-8110  | Next

Determinants of SARS-CoV-2 anti-spike antibody levels following BNT162b2 vaccination: cross-sectional analysis of 6,000 SIREN study participants
Otter, A. D., D'Arcangelo, S., Whitaker, H., Hewson, J., Foulkes, S., Atti, A., Cole, M., Linley, E., Tonge, S., Hettiarachchi, N., Sajedi, N., Calbraith, D., Norman, C., de Lacy, E., Price, L., Stewart, S., Cromey, L., Corrigan, D., SIREN study group, , Rowe, C., Brown, C., Islam, J., Semper, A., Hopkins, S., Hall, V., Brooks, T.
10.1101/2022.04.21.22274025 — Posted: 2022-04-21
Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy
McCreary, E. K., Lemon, L., Megli, C., Oakes, A., Zapf, R. L., Kip, P. L., Seymour, C. W., UPMC Magee Monoclonal Antibody Treatment Group
10.1101/2022.04.20.22274090 — Posted: 2022-04-21
Accuracy of US CDC COVID-19 Forecasting Models
Chharia, A., Jeevan, G., Jha, R. A., Liu, M., Berman, J. M., Glorioso, C. A.
10.1101/2022.04.20.22274097 — Posted: 2022-04-21
The statistical analysis of daily data associated with different parameters of the New Coronavirus COVID-19 pandemic in Georgia and their monthly interval prediction from January 1, 2022 to March 31, 2022
Amiranashvili, A. G., Khazaradze, K. R., Japaridze, N. D.
10.1101/2022.04.19.22274044 — Posted: 2022-04-21
Effects of COVID-19 in Care Homes - A Mixed Methods Review
Heneghan, C., Dietrich, M., Brassey, J., Jefferson, T.
10.1101/2022.04.14.22273903 — Posted: 2022-04-20
Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study
Gram, M. A., Emborg, H.-D., Schelde, A. B., Friis, N. U., Nielsen, K. F., Moustsen-Helms, I. R., Legarth, R., Lam, J. U. H., Chaine, M., Malik, A. Z., Rasmussen, M., Fonager, J., Sieber, R. N., Stegger, M., Ethelberg, S., Valentiner-Branth, P., Hansen, C. H.
10.1101/2022.04.20.22274061 — Posted: 2022-04-20
Uncovering the structural flexibility of SARS-CoV-2 glycoprotein spike variants
Arruda, H. R. S., Lima, T. M., Alvim, R. G. F., Victorio, F. B. A., Abreu, D. P. B., Marsili, F. F., Cruz, K. D., Sosa-Acosta, P., Quinones-Vega, M., Guedes, J. S., Nogueira, F. C. S., Silva, J. L., Castilho, L. R., de Oliveira, G. A. P.
10.1101/2022.04.20.488873 — Posted: 2022-04-20
Emergence of new subgenomic mRNAs in SARS-CoV-2
Mears, H. V., Young, G. R., Sanderson, T., Harvey, R., Crawford, M., Snell, D. M., Fowler, A. S., Hussain, S., Nicod, J., Peacock, T. P., Emmott, E., Finsterbusch, K., Luptak, J., Wall, E., Williams, B., Gandhi, S., Swanton, C., Bauer, D. L.
10.1101/2022.04.20.488895 — Posted: 2022-04-20
Compellingly high SARS-CoV-2 susceptibility of Golden Syrian hamsters suggests multiple zoonotic infections of pet hamsters during the COVID-19 pandemic
Blaurock, C., Breithaupt, A., Weber, S., Wylezich, C., Keller, M., Mohl, B.-P., Goerlich, D., Groschup, M. H., Sadeghi, B., Hoeper, D., Mettenleiter, T. C., Balkema-Buschmann, A.
10.1101/2022.04.19.488826 — Posted: 2022-04-20
Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model
Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., Schön, J., Wernike, K., Widera, M., Ciesek, S., Mueller, S. O., Mettenleiter, T. C., Petsch, B., Beer, M., Dorhoi, A.
10.1101/2022.04.20.485440 — Posted: 2022-04-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).